TheraVet SA (ALVET.PA)

0.5160 -0.0120 (-2.27%) 市場開市。 截至 11:24AM CEST。

TheraVet SA

Avenue Jean Mermoz 32/1
Gosselies 6041
Belgium

https://www.thera.vet/en

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Enrico Bastianelli M.B.A., M.D., MBA	Founder, CEO & Director	無	無	1969
Mr. Rodolphe Lebrun	Chief Financial Officer	無	無	無
Ms. Sabrina Ena Ph.D.	Chief Operating Officer	無	無	無
Fanny Guillerminet	Managing Director of the US Subsidiary	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET, an injectable self-hardening phosphocalcic bone void filler for osteointegration, osteoinduction, and bone remodeling properties; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid, species specific plasma, and an active pharmaceutical component. The company also provides various products, such as BIOCERA-VET bone surgery RTU, a ready-to-use highly injectable self-hardening calcium-phosphate cement; BIOCERA-VET smartgraft, a naturally osteoconductive bone graft; BIOCERA-VET granules, an affordable biocompatible calcium-phosphate bone substitute; and BIOCERA-VET osteosarcoma RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty. TheraVet SA was incorporated in 2017 and is based in Gosselies, Belgium.

公司管治

截至 無 止，TheraVet SA 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。